Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex 4.0 mg/kg in Subjects With Normal or Severely Impaired Renal Function
NCT00702715Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2008
- Primary completion
- Mar 2010
- Modality
- Biodegradable Polymers, Small Molecules
01
Overview
Phase 3, open-label trial of Sugammadex in neuromuscular blockade (NMB) (2 arms), sponsored by Merck & Co. Primary endpoint: Time to Recovery of the T4/T1 Ratio to 0.9. Started Sep 2008; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT00702715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00702715.